September 25, 2012 (Phoenix, Arizona) — Patients with chronic pain who require high doses of opioids to achieve pain relief show exceptionally high rates of defects of the cytochrome P450 (CYP450) ...

Alexis Garcia, PharmD, senior director of business development at Tabula Rasa HealthCare, outlines how cytochrome P450 enzymes can impact medication efficacy in patients taking multiple drugs. So the ...

Aim: The present study aimed to investigate the human genetic diversity of the CYP450 superfamily in order to identify functional interethnic differences and analyze the role of CYP450 enzymes in ...

Cytochrome P450 enzymes constitute a superfamily of haem-containing proteins that catalyse the oxidation of a wide range of exogenous and endogenous compounds. Their function is fundamental to the ...

The majority of drug interactions today are attributed to the cytochrome P450 (CYP450) isoenzyme system. However, new data suggest that transport proteins also play a key role. One such transporter is ...

This statement summarizes the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommendations regarding CYP450 genetic testing in adult patients beginning treatment ...

Phase I study of docetaxel and temsirolimus in refractory solid tumors. Background: Interactions of cytochrome P450 (CYP), especially CYP3A4, between chemotherapy agents and other xenobiotics can ...

Pharmacokinetic drug-drug interactions (DDIs) involving opioid analgesics can be problematic. Opioids are widely used, have a narrow therapeutic index, and can be associated with severe toxicity. The ...

The company said it is believed to be the first clinical lab to offer testing for variants in all cytochrome P450 genes known to influence the CYP450 enzyme system, which affects the metabolism of ...

THERE ARE MANY REASONS that promising drugs wash out during pharmaceutical development, and one of them is cytochrome P450. A set of enzymes mostly produced in the liver, CYP450, as it is commonly ...

Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC). This is an ASCO Meeting Abstract from the 2011 ASCO ...